Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENELUX CorpGNLX · Entity 1116 | Chief Financial Officer | December 18, 2024 | December 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENELUX Corp
Report date December 18, 2024 · Filed December 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,452 |
Reported balance
After 2024-12-18 transaction · row 1
1 source rowRow 1 · 2024-12-18 · Grant · Acquired 41,650 · Balance 82,452 F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. 25% of the RSUs vest on August 1, 2025, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2034-12-17 | Direct | 56,525 |
Reported balance
After 2024-12-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-18 · Grant · Acquired 56,525 · Balance 56,525 F2: 25% of the shares vest on August 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. 25% of the RSUs vest on August 1, 2025, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
F2: 25% of the shares vest on August 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2024 Filed Dec 21, 2024 01:44 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (right to buy) · Derivative | 56,525 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001415889-24-030003 · form4-12212024_011241.xml · derivative · entry 2 Zak Lourie S. · CIK 0001991207 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,525 Underlying: Common Stock · 56,525 shares Expires 2034-12-17 F2 · derivative.exercise_date: 25% of the shares vest on August 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| December 18, 2024 Filed Dec 21, 2024 01:44 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 41,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030003 · form4-12212024_011241.xml · nonDerivative · entry 1 Zak Lourie S. · CIK 0001991207 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,452 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. 25% of the RSUs vest on August 1, 2025, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:35 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 2,103 | $2.34 | $4,921.02 |
DisclosureSEC source: 0001415889-24-029744 · form4-12182024_041208.xml · nonDerivative · entry 1 Zak Lourie S. · CIK 0001991207 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,802 F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. F2 · balance_after: Includes 4,477 shares acquired under the Issuer's Employee Stock Purchase Plan on November 15, 2024. Read SEC document |
| May 29, 2024 Filed Jun 8, 2024 01:40 UTC | GENELUX Corp GNLX · Entity 1116 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 31,250 | Not disclosed Strike: $5.25 | Not disclosed |
DisclosureSEC source: 0001415889-24-016097 · form4-06072024_090601.xml · derivative · entry 2 Zak Lourie S. · CIK 0001991207 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2029-05-29 F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00. Read SEC document |
| May 29, 2024 Filed Jun 8, 2024 01:40 UTC | GENELUX Corp GNLX · Entity 1116 | PurchaseCommon Stock | 31,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-016097 · form4-06072024_090601.xml · nonDerivative · entry 1 Zak Lourie S. · CIK 0001991207 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00. Read SEC document |
| March 14, 2024 Filed Jul 8, 2024 20:30 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 3,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019346 · form4-07082024_040715.xml · nonDerivative · entry 2 Zak Lourie S. · CIK 0001991207 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,428 F2 · kind: Represents RSUs that are fully vested as of March 14, 2024. F3 · balance_after: Includes 2,106 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2024. Read SEC document |
| February 19, 2024 Filed Jul 8, 2024 20:30 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 1,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019346 · form4-07082024_040715.xml · nonDerivative · entry 1 Zak Lourie S. · CIK 0001991207 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,470 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 20:19 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001209191-23-049093 · doc4.xml · derivative · entry 1 Zak Lourie S. · CIK 0001991207 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-09-10 F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.